Asset profile
nitric oxide · INOmax
Other
Approvedregulatory verdict
Evidence outlook
Approved: Hypertension
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
60 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Nitric Oxide (INOmax): this drug | Approved | Gas (inhaled) | Nitric oxide | ||
| Aprocitentan (Tryvio) | Approved | Small molecule | Endothelin receptor (ETA/ETB, dual) | ||
| Baxdrostat (Baxfendy) | Approved | Small molecule | Aldosterone synthase (CYP11B2) | ||
| Bosentan (Tracleer) | Approved | Small molecule | Endothelin receptor (ETA/ETB, dual) | ||
| Epoprostenol (Flolan) | Approved | Small molecule | IP receptor (prostacyclin pathway) | ||
| Sacubitril / Valsartan (Entresto) | Approved | Small molecule | Neprilysin + Angiotensin II receptor (dual) | ||
| Treprostinil (Orenitram / Remodulin / Tyvaso) | Approved | Small molecule | IP receptor (prostacyclin pathway) | ||
| Treprostinil (Yutrepia, Liquidia) | Approved | Small molecule | IP receptor (prostacyclin pathway) | ||
| AD-209 | Phase 3 | Small molecule | Angiotensin II type 1 receptor / L-type calcium channel / Na-Cl cotransporter | ||
| AGSAVI | Phase 3 | Small molecule | Angiotensin II receptor / Calcium channel / Thiazide-like diuretic | ||
| AJU-C52 | Phase 3 | Small molecule | Angiotensin II receptor / Calcium channel / Thiazide-like diuretic | ||
| Ambrisentan (Letairis) | Phase 3 | Small molecule | Endothelin A receptor | ||
| C2402 | Phase 3 | Small molecule | — | ||
| CJ-30060 | Phase 3 | Small molecule | Angiotensin II receptor / Calcium channel / HMG-CoA reductase | ||
| CJ-30061 | Phase 3 | Small molecule | Angiotensin II receptor / Calcium channel / HMG-CoA reductase | ||
| DWC202206 + DWC202207 | Phase 3 | Small molecule | — |
…and 45 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(24 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (8)
November 2026 (1)
Phase 1Healthy SubjectsActive not recruiting
Est. primary completion 2026-11 · NCT05612074 · CT.gov ↗
What to watch
December 2026 (7)
Phase 1Critical Illness, PneumoniaRecruiting
Est. primary completion 2026-12 · NCT06950294 · CT.gov ↗
What to watch
Phase 1E-cigarette UseRecruiting
Est. primary completion 2026-12 · NCT06159608 · CT.gov ↗
What to watch
Early phase / not applicableCardiovascular DiseaseActive not recruiting
Est. primary completion 2026-12 · NCT02115724 · CT.gov ↗
What to watch
Early phase / not applicableHealthy Subjects With Low Energy LevelsRecruiting
Est. primary completion 2026-12-25 · NCT07729943 · CT.gov ↗
What to watch
Early phase / not applicableHealthy, UnconsciousEnrolling by invitation
Est. primary completion 2026-12-30 · NCT04903535 · CT.gov ↗
What to watch
Early phase / not applicablePersistent Pulmonary Hypertension of the Newborn, Inhaled Nitric OxideRecruiting
Est. primary completion 2026-12-31 · NCT06832163 · CT.gov ↗
What to watch
Early phase / not applicableLiver Diseases, Reperfusion Injury, VasoplegiaNot yet recruiting
Est. primary completion 2026-12-31 · NCT07125443 · CT.gov ↗
What to watch
2027 (3)
June 2027 (1)
Phase 3AKI, CHD - Congenital Heart Disease, SurgeryRecruiting
Est. primary completion 2027-06-30 · NCT04216927 · CT.gov ↗
What to watch
2028 (12)
January 2028 (1)
Early phase / not applicableIdiopathic BronchiectasisRecruiting
Est. primary completion 2028-01-31 · NCT07566611 · CT.gov ↗
What to watch
February 2028 (2)
March 2028 (2)
Phase 2Traumatic Brain InjuryEnrolling by invitation
Est. primary completion 2028-03-28 · NCT05616910 · CT.gov ↗
What to watch
Phase 3Nitric Oxide, Cardiac Surgery, Cardiopulmonary Bypass, Adult Patients Undergoing Cardiovascular Surgery With Cardiopulmonary BypassRecruiting
Est. primary completion 2028-03-31 · NCT06702553 · CT.gov ↗
What to watch
May 2028 (1)
Early phase / not applicablePost Traumatic Stress Disorder, TraumaRecruiting
Est. primary completion 2028-05-01 · NCT07485231 · CT.gov ↗
What to watch
July 2028 (1)
Phase 2Airway DiseaseEnrolling by invitation
Est. primary completion 2028-07-15 · NCT04738422 · CT.gov ↗
What to watch
August 2028 (1)
Phase 1Cerebrovascular Disorders, Acute Cerebrovascular DiseaseRecruiting
Est. primary completion 2028-08-01 · NCT05871606 · CT.gov ↗
What to watch
October 2028 (2)
Early phase / not applicableObesity, Respiratory Insufficiency, Hypoxemic Respiratory Failure, Nitric OxideNot yet recruiting
Est. primary completion 2028-10 · NCT06675435 · CT.gov ↗
What to watch
Early phase / not applicableCardiac Surgery Associated - Acute Kidney Injury, Cardiac Surgery With Cardiopulmonary BypassNot yet recruiting
Est. primary completion 2028-10-31 · NCT07544147 · CT.gov ↗
What to watch
December 2028 (2)
Phase 4Congenital Diaphragmatic Hernia, Pulmonary HypertensionNot yet recruiting
Est. primary completion 2028-12 · NCT07247240 · CT.gov ↗
What to watch
Early phase / not applicableAcute Respiratory Distress Syndrome, Ventilation Perfusion MismatchRecruiting
Est. primary completion 2028-12-31 · NCT05801224 · CT.gov ↗
What to watch
2030 (1)
October 2030 (1)
Phase 4Congenital Diaphragmatic HerniaRecruiting
Est. primary completion 2030-10-31 · NCT05213676 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.